SEC ownership of bioAffinity Technologies, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001712762.

Comparable stake leader

Richard K. Crumly

Disclosed value leader

Gary D. Rubin

Comparable rows

2/40

Latest evidence

30 Jun 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
2 of 40
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
Richard K. Crumly
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
30 Jun 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001712762
Issuer location
San Antonio, TX

Ownership snapshot

Top shareholders of bioAffinity Technologies, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Richard K. Crumly
Disclosed value leader
Gary D. Rubin
Comparable rows
2/40
Latest evidence
30 Jun 2026
13D/G 3/4/5 13F Lead comparable stake: 11% 38 rows are not safely comparable across share classes. 13D/G row: Richard K. Crumly Showing 1-8 of 40 holder rows.

Quick read

Richard K. Crumly leads the comparable SEC ownership view at 11%.

2 of 40 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Richard K. Crumly's linked filing trail.
Comparable ownership Top 2
Richard K. Crumly 11%
BIGGER CAPITAL FUND L P 5.8%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 40 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Richard K. Crumly
13D/G
11%
Reported 13D/G · 07 May 2025
$1,446,200
3,213,777 shares
$0 07 May 2025
BIGGER CAPITAL FUND L P
13D/G
Bigger Michael
5.8%
Reported 13D/G · 29 Sep 2025
—
117,364 shares
$0 29 Sep 2025
Gary D. Rubin
3/4/5
Director, 10%+ Owner
—
denominator unverified
$4,586,464
1,730,741 shares
— 01 Jul 2024
Nathan M. Perlmutter
3/4/5
10%+ Owner
—
mixed-class rows
$2,213,386
399,653 shares
mixed-class rows
— 06 Sep 2022
Steven Girgenti
3/4/5
Executive Chairman, Director
—
denominator unverified
$2,846,638
1,089,017 shares
— 10 Jan 2025
Roby Joyce
3/4/5
Director
—
denominator unverified
$1,721,825
649,745 shares
— 01 Jul 2024
Maria Zannes
3/4/5
President & CEO, Director
—
denominator unverified
$644,803
280,359 shares
— 10 Jan 2025
Robert A. Anderson
3/4/5
Director
—
denominator unverified
$434,430
163,936 shares
— 01 Jul 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

No eligible buy or sell activity is available for this window. No eligible Buy or Sell transactions are available in this dataset since 12 Nov 2025.

Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-17 of 17 reporting-owner rows connected to bioAffinity Technologies, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
17
Largest Forms 3/4/5 holder
Gary D. Rubin
Net 12M change
$0
Latest report
12 Aug 2025
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Gary D. Rubin Director, 10%+ Owner $4,586,464 Mixed 01 Jul 2024
Steven Girgenti Executive Chairman, Director $2,846,638 Mixed 10 Jan 2025
Nathan M. Perlmutter 10%+ Owner $2,213,386 Mixed 06 Sep 2022
Roby Joyce Director $1,721,825 Mixed 01 Jul 2024
Maria Zannes President & CEO, Director $644,803 Mixed 10 Jan 2025
Robert A. Anderson Director $434,430 Mixed 01 Jul 2024
Peter S. Knight Director $311,256 Mixed 01 Jul 2024
James Michael Edwards VP and CFO $301,983 Mixed 10 Jan 2025
Stuart Diamond Director $262,583 Mixed 01 Jul 2024
Mohsin Y. Meghji Director $162,411 Mixed 01 Oct 2023
Jamie Platt Director $145,082 Mixed 01 Jul 2024
Michael Philip Dougherty Chief Financial Officer $124,620 Mixed 31 Jan 2024
Timothy P. Zannes Secretary, EVP, Gen. Counsel $119,000 Mixed 10 Jan 2025
Vivienne I. Rebel Chief Sci. & Med. Officer, EVP $68,417 Mixed 31 Jan 2024
Xavier T. Reveles Chief Operating Officer $30,102 Mixed 10 Jan 2025
Roberto Rios Director $208 Mixed 12 Aug 2025
John J. Oppenheimer Director Mixed 12 Aug 2025

Recent insider transactions for bioAffinity Technologies, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
No insider transactions were found in the last 12 months for this issuer.
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .